On the one hand, we think that more in-depth biochemical analyses should be carried out, establishing blood levels of vitamin D in the form of its metabolites 25-hydroxyvitamin D or calcidiol, and mainly 1.25-dihydroxyvitamin D or calcitriol as the active metabolite of the vitamin, which would allow MS patients to be categorized according to their vitamin D status and then be compared with serum IL-6 levels. This evidence concerns the gene IL6 and myeloid sarcoma.